These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 33540543)

  • 1. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy.
    Mercogliano MF; Bruni S; Mauro F; Elizalde PV; Schillaci R
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing NK Cells for Cancer Treatment.
    Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
    Front Immunol; 2019; 10():2836. PubMed ID: 31867006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer.
    Mercogliano MF; Bruni S; Elizalde PV; Schillaci R
    Front Oncol; 2020; 10():584. PubMed ID: 32391269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.
    Hargadon KM
    Clin Transl Med; 2020 Jan; 10(1):374-411. PubMed ID: 32508018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes.
    Pesce S; Trabanelli S; Di Vito C; Greppi M; Obino V; Guolo F; Minetto P; Bozzo M; Calvi M; Zaghi E; Candiani S; Lemoli RM; Jandus C; Mavilio D; Marcenaro E
    Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33255582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.
    Qu X; Tang Y; Hua S
    Front Immunol; 2018; 9():563. PubMed ID: 29662489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
    Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
    Front Immunol; 2019; 10():1782. PubMed ID: 31456796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diversity of immune checkpoints in cancer immunotherapy.
    Guo Z; Zhang R; Yang AG; Zheng G
    Front Immunol; 2023; 14():1121285. PubMed ID: 36960057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
    Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):499-507. PubMed ID: 29327244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing NK Cell Checkpoint-Modulating Immunotherapies.
    Chauhan SKS; Koehl U; Kloess S
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32640575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
    Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
    JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor immunotherapy: New aspects of natural killer cells.
    Li Y; Sun R
    Chin J Cancer Res; 2018 Apr; 30(2):173-196. PubMed ID: 29861604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal human CD4(+) helper T cells express Kv1.1 voltage-gated K(+) channels, and selective Kv1.1 block in T cells induces by itself robust TNFα production and secretion and activation of the NFκB non-canonical pathway.
    Fellerhoff-Losch B; Korol SV; Ganor Y; Gu S; Cooper I; Eilam R; Besser M; Goldfinger M; Chowers Y; Wank R; Birnir B; Levite M
    J Neural Transm (Vienna); 2016 Mar; 123(3):137-57. PubMed ID: 26611796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.